Ventilation imaging to guide lung radiotherapy in non-small cell lung cancer
Official title: Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy
Run by University of Sydney · NCT06159660 · Data updated 2026-11-12
This study tests whether using lung ventilation imaging can help plan radiotherapy for people with stage II–IV NSCLC to reduce lung toxicity.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | University of Sydney Academic / other |
| Drugs / interventions | chemotherapy, radiation, immunotherapy |
| Locations | 1 site (St Leonards, New South Wales) |
| Status | Recruiting |
| Started | February 17, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT06159660 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older with histologically confirmed stage II–IV NSCLC, ECOG 0–2, eligible for non-SABR external beam radiotherapy with curative or palliative intent, and having usable pulmonary function tests and 4DCT simulation.
✕Probably not a fit
Patients not expected to benefit are those with prior thoracic radiation, prior thoracic cancer surgery, prior chemotherapy for this cancer, or insufficient baseline imaging/lung function data.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to validate how fluoroscopic and CT ventilation imaging can be integrated into non-SABR external beam radiotherapy for stage II–IV non-small cell lung cancer. Researchers will compare functional avoidance plans against standard plans to understand dosimetric differences and establish quality assurance and accuracy thresholds. Eligible participants will undergo standard 4DCT simulation, pulmonary function tests, additional ventilation imaging, and SPECT imaging before receiving radiotherapy, with follow-up for up to one year. The study addresses the limitations of assuming uniform lung function by exploring regional lung function in treatment planning. A lead sponsor is the University of Sydney with NHMRC and regional collaborators, at Royal North Shore Hospital.
Why it matters
Potential benefit: If successful, patients could receive radiotherapy that better spares functional lung tissue, potentially reducing toxicity.
How similar studies have gone: Other efforts in functional lung avoidance radiation therapy have shown promise in planning improvements, but this specific imaging-guided approach is being validated in a prospective observational framework.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Histologically proven Stage II-IV non-small cell lung cancer as determined using the IASLC International Association for the Study of Lung Cancer (IASLC) 8th edition lung cancer staging guidelines. * To be treated with curative intent (stage II-III) or palliative intent (stage IV) with non-SABR external beam radiotherapy (e.g. 60 Gy in 30 treatments for curative intent or 30 Gy in 5 treatments for palliative intent). * Pulmonary function tests within 8 weeks of registration. * 4DCT simulation for radiation therapy. * Willingness to give written informed consent. * Willingness and ability to comply with the study procedures and visit requirements. * Available for follow up for 1 year or until death, whichever occurs first. Exclusion Criteria: * Prior radiation therapy to the thorax. * Prior surgery for this cancer. * Prior chemotherapy for this cancer. * Interstitial lung disease. * Pregnant women.
Where it's running
-
Royal North Shore Hospital
St Leonards, New South Wales, Australia Recruiting
Study contacts
- Principal investigator: Dasantha Jayamanne — Northern Sydney Local Health District
- Study coordinator: Clinical Trial Coordinator
- Email: Shona.Silvester@sydney.edu.au
- Phone: +61 2 8627 1185
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A new treatment model for elderly lung cancer patients
This trial tests a comprehensive, integrated care approach for older adults with lung cancer to improve perioperative management and outcomes.
-
Investigational antibody–drug conjugates for previously treated stage IV squamous non-small cell lung cancer
This trial tests whether antibody–drug conjugates can shrink or control metastatic squamous non-small cell lung cancer in people whose cancer progressed after immunotherapy and platinum chemotherapy.
-
Bright-light exposure and exercise program for cancer patients
This study is testing if a six-week program that combines bright-light exposure with exercise can help people with lung and esophageal cancer feel better and improve their quality of life.
-
Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations
This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.
-
Registry for thoracic surgery procedures in Spain
This study is creating a national database to see how new surgical techniques and technologies in thoracic surgery can improve care and outcomes for patients in Spain.
-
Treatment with STAR0602 for advanced solid tumors
This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.